Ignite Creation Date:
2024-10-25 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06508684
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-14
Brief Title:
Current Status of BTKi Treatment for CLLSLL in China
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma Undergoing Treatment With Brutons Tyrosine Kinase Inhibitors
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BTKi has become the standard treatment regimen for CLLSLLthere is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors Therefore we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLLSLL patients in China and the related influencing factors and to explore more suitable treatment patterns based on this
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None